Cencora Inc. (COR)vsVale SA ADR (VALE)
COR
Cencora Inc.
$269.36
+2.53%
HEALTHCARE · Cap: $51.53B
VALE
Vale SA ADR
$16.25
-1.81%
BASIC MATERIALS · Cap: $70.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 53% more annual revenue ($328.68B vs $214.86B). VALE leads profitability with a 7.3% profit margin vs 0.8%. VALE appears more attractively valued with a PEG of 0.34. VALE earns a higher WallStSmart Score of 67/100 (B-).
COR
Buy64
out of 100
Grade: C+
VALE
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.6%
Fair Value
$179.81
Current Price
$269.36
$89.55 premium
Margin of Safety
+81.8%
Fair Value
$95.44
Current Price
$16.25
$79.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 75 in profit
Earnings expanding 128.3% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 1.2B in free cash flow
Growing faster than its price suggests
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 28.1%
Earnings expanding 22.0% YoY
Areas to Watch
Trading at 15.4x book value
3.8% revenue growth
0.8% margin — thin
Operating margin of 1.7%
2.7% revenue growth
ROE of 6.8% — below average capital efficiency
7.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, EPS Growth, Altman Z-Score. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : VALE
The strongest argument for VALE centers on PEG Ratio, Market Cap, Price/Book. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bear Case : COR
The primary concerns for COR are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 3.65 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Bear Case : VALE
The primary concerns for VALE are Revenue Growth, Return on Equity, Profit Margin.
Key Dynamics to Monitor
VALE carries more volatility with a beta of 0.75 — expect wider price swings.
COR is growing revenue faster at 3.8% — sustainability is the question.
COR generates stronger free cash flow (1.2B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VALE scores higher overall (67/100 vs 64/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?